{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T20:59:02Z","timestamp":1795294742600,"version":"4.10.3"},"reference-count":210,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Temozolomide (TMZ), an oral alkylating prodrug which delivers a methyl group to purine bases of DNA (O6-guanine; N7-guanine and N3-adenine), is frequently used together with radiotherapy as part of the first-line treatment of high-grade gliomas. The main advantages are its high oral bioavailability (almost 100% although the concentration found in the cerebrospinal fluid was approximately 20% of the plasma concentration of TMZ), its lipophilic properties, and small size that confer the ability to cross the blood-brain barrier. Furthermore, this agent has demonstrated activity not only in brain tumors but also in a variety of solid tumors. However, conventional therapy using surgery, radiation, and TMZ in glioblastoma results in a median patient survival of 14.6 months. Treatment failure has been associated with tumor drug resistance. This phenomenon has been linked to the expression of O6-methylguanine-DNA methyltransferase, but the mismatch repair system and the presence of cancer stem-like cells in tumors have also been related to TMZ resistance. The understanding of these mechanisms is essential for the development of new therapeutic strategies in the clinical use of TMZ, including the use of nanomaterial delivery systems and the association with other chemotherapy agents. The aim of this review is to summarize the resistance mechanisms of TMZ and the current advances to improve its clinical use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1570159x18666200626204005","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T15:53:57Z","timestamp":1593186837000},"page":"513-537","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications"],"prefix":"10.2174","volume":"19","author":[{"given":"Ra\u00fal","family":"Ortiz","sequence":"first","affiliation":[{"name":"Institute of Biopathology and Regenerative Medicine (IBIMER), Biomedical Research Centre (CIBM), University of Granada,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Perazzoli","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Almeria,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cabeza","sequence":"additional","affiliation":[{"name":"Institute of Biopathology and Regenerative Medicine (IBIMER), Biomedical Research Centre (CIBM), University of Granada,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Jim\u00e9nez-Luna","sequence":"additional","affiliation":[{"name":"Department of Oncology, Ludwig Institute for Cancer Research, University of Lausanne, Epalinges 1066,Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Luque","sequence":"additional","affiliation":[{"name":"Medical Oncology Service, Virgen de las Nieves Hospital, Granada,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Prados","sequence":"additional","affiliation":[{"name":"Institute of Biopathology and Regenerative Medicine (IBIMER), Biomedical Research Centre (CIBM), University of Granada,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consolaci\u00f3n","family":"Melguizo","sequence":"additional","affiliation":[{"name":"Institute of Biopathology and Regenerative Medicine (IBIMER), Biomedical Research Centre (CIBM), University of Granada,Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1586\/14737140.6.8.1187","volume":"6","author":"Mutter N.","year":"2006","unstructured":"Mutter N.; Stupp R.; Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther 2006,6(8),1187-1204","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/0008-5472.CAN-16-2983","volume":"77","author":"Thomas A.","year":"2017","unstructured":"Thomas A.; Tanaka M.; Trepel J.; Reinhold W.C.; Rajapakse V.N.; Pommier Y.; Temozolomide in the era of precision medicine. Cancer Res 2017,77(4),823-826","journal-title":"Cancer Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1874467211205010102","volume":"5","author":"Zhang J.","year":"2012","unstructured":"Zhang J.; Stevens M.F.G.; Bradshaw T.D.; Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol 2012,5(1),102-114","journal-title":"Curr Mol Pharmacol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"9045","DOI":"10.1021\/bi00197a003","volume":"33","author":"Denny B.J.","year":"1994","unstructured":"Denny B.J.; Wheelhouse R.T.; Stevens M.F.G.; Tsang L.L.H.; Slack J.A.; NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994,33(31),9045-9051","journal-title":"Biochemistry"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejpb.2019.01.015","volume":"136","author":"Ramalho M.J.","year":"2019","unstructured":"Ramalho M.J.; Andrade S.; Coelho M.A.N.; Loureiro J.A.; Pereira M.C.; Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for glioblastoma multiforme therapy. Eur J Pharm Biopharm 2019,136,156-163","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=6","volume":"7","author":"St&#xE9;phanou A.","year":"2019","unstructured":"St&#xE9;phanou A.; Ballesta A.; pH as a potential therapeutic target to improve temozolomide antitumor efficacy: A mechanistic modeling study. Pharmacol Res Perspect 2019,7(1)","journal-title":"Pharmacol Res Perspect"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3390\/ijms19030889","volume":"19","author":"Pawlowska E.","year":"2018","unstructured":"Pawlowska E.; Szczepanska J.; Szatkowska M.; Blasiak J.; An Interplay between senescence, apoptosis and autophagy in glioblastoma multiforme-role in pathogenesis and therapeutic perspective. Int J Mol Sci 2018,19(3),889","journal-title":"Int J Mol Sci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1023\/A:1022592913323","volume":"61","author":"Patel M.","year":"2003","unstructured":"Patel M.; McCully C.; Godwin K.; Balis F.M.; Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 2003,61(3),203-207","journal-title":"J Neurooncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1158\/1078-0432.CCR-03-0807","volume":"10","author":"Ostermann S.","year":"2004","unstructured":"Ostermann S.; Csajka C.; Buclin T.; Leyvraz S.; Lejeune F.; Decosterd L.A.; Stupp R.; Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004,10(11),3728-3736","journal-title":"Clin Cancer Res"},{"key":"ref=10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114311","volume":"9","author":"Liu H.L.","year":"2014","unstructured":"Liu H.L.; Huang C.Y.; Chen J.Y.; Wang H.Y.; Chen P.Y.; Wei K.C.; Pharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment. PLoS One 2014,9(12)","journal-title":"PLoS One"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s12094-017-1763-6","volume":"20","author":"Mart&#xED;nez-Garcia M.","year":"2018","unstructured":"Mart&#xED;nez-Garcia M.; &#xC1;lvarez-Linera J.; Carrato C.; Ley L.; Luque R.; Maldonado X.; Mart&#xED;nez-Aguillo M.; Navarro L.M.; Vaz-Salgado M.A.; Gil-Gil M.; SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). Clin Transl Oncol 2018,20(1),22-28","journal-title":"Clin Transl Oncol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/neuonc\/nop030","volume":"12","author":"Kong D.S.","year":"2010","unstructured":"Kong D.S.; Lee J.I.; Kim J.H.; Kim S.T.; Kim W.S.; Suh Y.L.; Dong S.M.; Nam D.H.; Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro-oncol 2010,12(3),289-296","journal-title":"Neuro-oncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"Stupp R.","year":"2009","unstructured":"Stupp R.; Hegi M.E.; Mason W.P.; van den Bent M.J.; Taphoorn M.J.B.; Janzer R.C.; Ludwin S.K.; Allgeier A.; Fisher B.; Belanger K.; Hau P.; Brandes A.A.; Gijtenbeek J.; Marosi C.; Vecht C.J.; Mokhtari K.; Wesseling P.; Villa S.; Eisenhauer E.; Gorlia T.; Weller M.; Lacombe D.; Cairncross J.G.; Mirimanoff R.O.; European organisation for research and treatment of cancer brain tumour and radiation oncology groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009,10(5),459-466","journal-title":"Lancet Oncol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11060-017-2668-5","volume":"136","author":"Lin A.J.","year":"2018","unstructured":"Lin A.J.; Campian J.L.; Hui C.; Rudra S.; Rao Y.J.; Thotala D.; Hallahan D.; Huang J.; Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. J Neurooncol 2018,136(2),403-411","journal-title":"J Neurooncol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/neuonc\/noy072","volume":"20","author":"Karachi A.","year":"2018","unstructured":"Karachi A.; Dastmalchi F.; Mitchell D.A.; Rahman M.; Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro-oncol 2018,20(12),1566-1572","journal-title":"Neuro-oncol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11060-015-1841-y","volume":"124","author":"Campian J.L.","year":"2015","unstructured":"Campian J.L.; Ye X.; Gladstone D.E.; Ambady P.; Nirschl T.R.; Borrello I.; Golightly M.; King K.E.; Holdhoff M.; Karp J.; Drake C.G.; Grossman S.A.; Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas. J Neurooncol 2015,124(2),307-316","journal-title":"J Neurooncol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1200\/JCO.2004.07.060","volume":"22","author":"Su Y.B.","year":"2004","unstructured":"Su Y.B.; Sohn S.; Krown S.E.; Livingston P.O.; Wolchok J.D.; Quinn C.; Williams L.; Foster T.; Sepkowitz K.A.; Chapman P.B.; Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004,22(4),610-616","journal-title":"J Clin Oncol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1212\/01.WNL.0000127617.89363.84","volume":"62","author":"Wick W.","year":"2004","unstructured":"Wick W.; Steinbach J.P.; K&#xFC;ker W.M.; Dichgans J.; Bamberg M.; Weller M.; One week on\/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 2004,62(11),2113-2115","journal-title":"Neurology"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.rmcr.2017.08.012","volume":"22","author":"Khan B.A.","year":"2017","unstructured":"Khan B.A.; Khan S.; White B.; Eranki A.; Severe pneumocystis jiroveci pneumonia in a patient on temozolomide therapy: A case report and review of literature. Respir Med Case Rep 2017,22,179-182","journal-title":"Respir Med Case Rep"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00262-016-1905-7","volume":"65","author":"Akasaki Y.","year":"2016","unstructured":"Akasaki Y.; Kikuchi T.; Homma S.; Koido S.; Ohkusa T.; Tasaki T.; Hayashi K.; Komita H.; Watanabe N.; Suzuki Y.; Yamamoto Y.; Mori R.; Arai T.; Tanaka T.; Joki T.; Yanagisawa T.; Murayama Y.; Phase I\/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma. Cancer Immunol Immunother 2016,65(12),1499-1509","journal-title":"Cancer Immunol Immunother"},{"key":"ref=21","first-page":"1124","volume":"4","author":"Geffen D.B.","year":"2002","unstructured":"Geffen D.B.; Man S.; New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J 2002,4(12),1124-1131","journal-title":"Isr Med Assoc J"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13046-016-0303-5","volume":"35","author":"Yan Y.","year":"2016","unstructured":"Yan Y.; Xu Z.; Dai S.; Qian L.; Sun L.; Gong Z.; Targeting autophagy to sensitive glioma to temozolomide treatment. J Exp Clin Cancer Res 2016,35,23","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","volume":"36","author":"Abbott N.J.","year":"2013","unstructured":"Abbott N.J.; Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis 2013,36(3),437-449","journal-title":"J Inherit Metab Dis"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"656","DOI":"10.2174\/138920111795164020","volume":"12","author":"Hartz A.M.S.","year":"2011","unstructured":"Hartz A.M.S.; Bauer B.; ABC transporters in the CNS - an inventory. Curr Pharm Biotechnol 2011,12(4),656-673","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/bs.acr.2014.10.002","volume":"125","author":"Miller D.S.","year":"2015","unstructured":"Miller D.S.; Regulation of ABC transporters blood-brain barrier: the good, the bad, and the ugly. Adv Cancer Res 2015,125,43-70","journal-title":"Adv Cancer Res"},{"key":"ref=26","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201702331","volume":"14","author":"Su B.","year":"2018","unstructured":"Su B.; Wang R.; Xie Z.; Ruan H.; Li J.; Xie C.; Lu W.; Wang J.; Wang D.; Liu M.; Effect of retro-inverso isomer of bradykinin on size-dependent penetration of blood-brain tumor barrier. Small 2018,14(7)","journal-title":"Small"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","volume":"19","author":"van Tellingen O.","year":"2015","unstructured":"van Tellingen O.; Yetkin-Arik B.; de Gooijer M.C.; Wesseling P.; Wurdinger T.; de Vries H.E.; Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat 2015,19,1-12","journal-title":"Drug Resist Updat"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.phrs.2007.08.003","volume":"56","author":"Marchesi F.","year":"2007","unstructured":"Marchesi F.; Turriziani M.; Tortorelli G.; Avvisati G.; Torino F.; De Vecchis L.; Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 2007,56(4),275-287","journal-title":"Pharmacol Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1158\/0008-5472.CAN-06-2782","volume":"67","author":"Blough M.D.","year":"2007","unstructured":"Blough M.D.; Zlatescu M.C.; Cairncross J.G.; O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells. Cancer Res 2007,67(2),580-584","journal-title":"Cancer Res"},{"key":"ref=30","first-page":"793","volume":"59","author":"Esteller M.","year":"1999","unstructured":"Esteller M.; Hamilton S.R.; Burger P.C.; Baylin S.B.; Herman J.G.; Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999,59(4),793-797","journal-title":"Cancer Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1215\/15228517-2008-090","volume":"11","author":"Kitange G.J.","year":"2009","unstructured":"Kitange G.J.; Carlson B.L.; Schroeder M.A.; Grogan P.T.; Lamont J.D.; Decker P.A.; Wu W.; James C.D.; Sarkaria J.N.; Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro-oncol 2009,11(3),281-291","journal-title":"Neuro-oncol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nrneurol.2009.197","volume":"6","author":"Weller M.","year":"2010","unstructured":"Weller M.; Stupp R.; Reifenberger G.; Brandes A.A.; van den Bent M.J.; Wick W.; Hegi M.E.; MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 2010,6(1),39-51","journal-title":"Nat Rev Neurol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","volume":"343","author":"Esteller M.","year":"2000","unstructured":"Esteller M.; Garcia-Foncillas J.; Andion E.; Goodman S.N.; Hidalgo O.F.; Vanaclocha V.; Baylin S.B.; Herman J.G.; Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000,343(19),1350-1354","journal-title":"N Engl J Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.2147\/OTT.S50208","volume":"6","author":"Thon N.","year":"2013","unstructured":"Thon N.; Kreth S.; Kreth F.W.; Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. OncoTargets Ther 2013,6,1363-1372","journal-title":"OncoTargets Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fonc.2015.00055","volume":"5","author":"Parker N.R.","year":"2015","unstructured":"Parker N.R.; Khong P.; Parkinson J.F.; Howell V.M.; Wheeler H.R.; Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol 2015,5,55","journal-title":"Front Oncol"},{"key":"ref=36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140131","volume":"10","author":"Perazzoli G.","year":"2015","unstructured":"Perazzoli G.; Prados J.; Ortiz R.; Caba O.; Cabeza L.; Berdasco M.; G&#xF3;nzalez B.; Melguizo C.; Temozolomide resistance in glioblastoma cell lines: implication of MGMT, MMR, P-Glycoprotein and CD133 expression. PLoS One 2015,10(10)","journal-title":"PLoS One"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"Hegi M.E.","year":"2005","unstructured":"Hegi M.E.; Diserens A.C.; Gorlia T.; Hamou M.F.; de Tribolet N.; Weller M.; Kros J.M.; Hainfellner J.A.; Mason W.; Mariani L.; Bromberg J.E.; Hau P.; Mirimanoff R.O.; Cairncross J.G.; Janzer R.C.; Stupp R.; MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005,352(10),997-1003","journal-title":"N Engl J Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1158\/1078-0432.CCR-03-0384","volume":"10","author":"Hegi M.E.","year":"2004","unstructured":"Hegi M.E.; Diserens A.C.; Godard S.; Dietrich P.Y.; Regli L.; Ostermann S.; Otten P.; Van Melle G.; de Tribolet N.; Stupp R.; Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004,10(6),1871-1874","journal-title":"Clin Cancer Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s11910-014-0507-z","volume":"15","author":"Taylor J.W.","year":"2015","unstructured":"Taylor J.W.; Schiff D.; Treatment considerations for MGMT-unmethylated glioblastoma. Curr Neurol Neurosci Rep 2015,15(1),507","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1016\/S1470-2045(14)70011-7","volume":"15","author":"Weller M.","year":"2014","unstructured":"Weller M.; van den Bent M.; Hopkins K.; Tonn J.C.; Stupp R.; Falini A.; Cohen-Jonathan-Moyal E.; Frappaz D.; Henriksson R.; Balana C.; Chinot O.; Ram Z.; Reifenberger G.; Soffietti R.; Wick W.; European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 2014,15(9),e395-e403","journal-title":"Lancet Oncol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/neuonc\/nop003","volume":"12","author":"Spiegl-Kreinecker S.","year":"2010","unstructured":"Spiegl-Kreinecker S.; Pirker C.; Filipits M.; L&#xF6;tsch D.; Buchroithner J.; Pichler J.; Silye R.; Weis S.; Micksche M.; Fischer J.; Berger W.; O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro-oncol 2010,12(1),28-36","journal-title":"Neuro-oncol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.critrevonc.2008.02.005","volume":"67","author":"Brandes A.A.","year":"2008","unstructured":"Brandes A.A.; Tosoni A.; Franceschi E.; Reni M.; Gatta G.; Vecht C.; Glioblastoma in adults. Crit Rev Oncol Hematol 2008,67(2),139-152","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"5743","DOI":"10.1200\/JCO.2009.23.0805","volume":"27","author":"Weller M.","year":"2009","unstructured":"Weller M.; Felsberg J.; Hartmann C.; Berger H.; Steinbach J.P.; Schramm J.; Westphal M.; Schackert G.; Simon M.; Tonn J.C.; Heese O.; Krex D.; Nikkhah G.; Pietsch T.; Wiestler O.; Reifenberger G.; von Deimling A.; Loeffler M.; Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009,27(34),5743-5750","journal-title":"J Clin Oncol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/nan.12415","volume":"44","author":"Dahlrot R.H.","year":"2018","unstructured":"Dahlrot R.H.; Dowsett J.; Fosmark S.; Malmstr&#xF6;m A.; Henriksson R.; Boldt H.; de Stricker K.; S&#xF8;rensen M.D.; Poulsen H.S.; Lysiak M.; S&#xF6;derkvist P.; Rosell J.; Hansen S.; Kristensen B.W.; Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis. Neuropathol Appl Neurobiol 2018,44(2),172-184","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40478-019-0745-z","volume":"7","author":"Radke J.","year":"2019","unstructured":"Radke J.; Koch A.; Pritsch F.; Schumann E.; Misch M.; Hempt C.; Lenz K.; L&#xF6;bel F.; Paschereit F.; Heppner F.L.; Vajkoczy P.; Koll R.; Onken J.; Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients. Acta Neuropathol Commun 2019,7(1),89","journal-title":"Acta Neuropathol Commun"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11060-019-03358-x","volume":"146","author":"Schaff L.R.","year":"2020","unstructured":"Schaff L.R.; Yan D.; Thyparambil S.; Tian Y.; Cecchi F.; Rosenblum M.; Reiner A.S.; Panageas K.S.; Hembrough T.; Lin A.L.; Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival. J Neurooncol 2020,146(1),163-170","journal-title":"J Neurooncol"},{"key":"ref=47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116518","volume":"408","author":"Marton E.","year":"2020","unstructured":"Marton E.; Giordan E.; Siddi F.; Curzi C.; Canova G.; Scarpa B.; Guerriero A.; Rossi S.; D\u2019 Avella D.; Longatti P.; Feletti A.; Over ten years overall survival in glioblastoma: A different disease? J Neurol Sci 2020,408","journal-title":"J Neurol Sci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2007.11.5964","volume":"26","author":"Hegi M.E.","year":"2008","unstructured":"Hegi M.E.; Liu L.; Herman J.G.; Stupp R.; Wick W.; Weller M.; Mehta M.P.; Gilbert M.R.; Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008,26(25),4189-4199","journal-title":"J Clin Oncol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1215\/15228517-2008-058","volume":"10","author":"Wick W.","year":"2008","unstructured":"Wick W.; Stupp R.; Beule A.C.; Bromberg J.; Wick A.; Ernemann U.; Platten M.; Marosi C.; Mason W.P.; van den Bent M.; Weller M.; Rorden C.; Karnath H.O.; A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro-oncol European Organisation for Research and Treatment of Cancer and the National Cancer Institute of Canada Clinical Trials Group2008,10(6),1019-1024","journal-title":"Neuro-oncol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/jnen\/nlz032","volume":"78","author":"Dahlrot R.H.","year":"2019","unstructured":"Dahlrot R.H.; Larsen P.; Boldt H.B.; Kreutzfeldt M.S.; Hansen S.; Hjelmborg J.B.; Kristensen B.W.; Post treatment effect of MGMT methylation level on glioblastoma survival. J Neuropathol Exp Neurol 2019,78(7),633-640","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ijc.26083","volume":"129","author":"Felsberg J.","year":"2011","unstructured":"Felsberg J.; Thon N.; Eigenbrod S.; Hentschel B.; Sabel M.C.; Westphal M.; Schackert G.; Kreth F.W.; Pietsch T.; L&#xF6;ffler M.; Weller M.; Reifenberger G.; Tonn J.C.; German Glioma Network. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 2011,129(3),659-670","journal-title":"Int J Cancer"},{"key":"ref=52","doi-asserted-by":"publisher","DOI":"10.3171\/2015.1.FOCUS14755","volume":"38","author":"Karsy M.","year":"2015","unstructured":"Karsy M.; Neil J.A.; Guan J.; Mahan M.A.; Colman H.; Jensen R.L.; Jensen R.L.; A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus 2015,38(3)","journal-title":"Neurosurg Focus"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0300-9084(01)01362-1","volume":"84","author":"Jacob S.","year":"2002","unstructured":"Jacob S.; Praz F.; DNA mismatch repair defects: role in colorectal carcinogenesis. Biochimie 2002,84(1),27-47","journal-title":"Biochimie"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1158\/1078-0432.CCR-08-1307","volume":"15","author":"Kinsella T.J.","year":"2009","unstructured":"Kinsella T.J.; Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. Clin Cancer Res 2009,15(6),1853-1859","journal-title":"Clin Cancer Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.pneurobio.2011.04.013","volume":"94","author":"Jeppesen D.K.","year":"2011","unstructured":"Jeppesen D.K.; Bohr V.A.; Stevnsner T.; DNA repair deficiency in neurodegeneration. Prog Neurobiol 2011,94(2),166-200","journal-title":"Prog Neurobiol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1158\/1078-0432.CCR-05-2543","volume":"12","author":"Liu L.","year":"2006","unstructured":"Liu L.; Gerson S.L.; Targeted modulation of MGMT: clinical implications. Clin Cancer Res 2006,12(2),328-331","journal-title":"Clin Cancer Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.drudis.2015.02.011","volume":"20","author":"Messaoudi K.","year":"2015","unstructured":"Messaoudi K.; Clavreul A.; Lagarce F.; Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. Drug Discov Today 2015,20(7),899-905","journal-title":"Drug Discov Today"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ctrv.2008.03.125","volume":"34","author":"Johannessen T.C.A.","year":"2008","unstructured":"Johannessen T.C.A.; Bjerkvig R.; Tysnes B.B.; DNA repair and cancer stem-like cells--potential partners in glioma drug resistance? Cancer Treat Rev 2008,34(6),558-567","journal-title":"Cancer Treat Rev"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","year":"2008","unstructured":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature Cancer Genome Atlas Research Network2008,455(7216),1061-1068","journal-title":"Nature"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1471-4159.2012.07781.x","volume":"122","author":"Happold C.","year":"2012","unstructured":"Happold C.; Roth P.; Wick W.; Schmidt N.; Florea A.M.; Silginer M.; Reifenberger G.; Weller M.; Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem 2012,122(2),444-455","journal-title":"J Neurochem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1158\/1078-0432.CCR-06-2149","volume":"13","author":"Cahill D.P.","year":"2007","unstructured":"Cahill D.P.; Levine K.K.; Betensky R.A.; Codd P.J.; Romany C.A.; Reavie L.B.; Batchelor T.T.; Futreal P.A.; Stratton M.R.; Curry W.T.; Iafrate A.J.; Louis D.N.; Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007,13(7),2038-2045","journal-title":"Clin Cancer Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1158\/1078-0432.CCR-08-3012","volume":"15","author":"Yip S.","year":"2009","unstructured":"Yip S.; Miao J.; Cahill D.P.; Iafrate A.J.; Aldape K.; Nutt C.L.; Louis D.N.; MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 2009,15(14),4622-4629","journal-title":"Clin Cancer Res"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1179\/016164110X12645013515052","volume":"32","author":"Stark A.M.","year":"2010","unstructured":"Stark A.M.; Doukas A.; Hugo H.H.; Mehdorn H.M.; The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma. Neurol Res 2010,32(8),816-820","journal-title":"Neurol Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.18632\/oncotarget.1302","volume":"4","author":"Shinsato Y.","year":"2013","unstructured":"Shinsato Y.; Furukawa T.; Yunoue S.; Yonezawa H.; Minami K.; Nishizawa Y.; Ikeda R.; Kawahara K.; Yamamoto M.; Hirano H.; Tokimura H.; Arita K.; Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma. Oncotarget 2013,4(12),2261-2270","journal-title":"Oncotarget"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1158\/1535-7163.MCT-18-0177","volume":"17","author":"Higuchi F.","year":"2018","unstructured":"Higuchi F.; Fink A.L.; Kiyokawa J.; Miller J.J.; Koerner M.V.A.; Cahill D.P.; Wakimoto H.; PLK1 inhibition targets myc-activated malignant glioma cells irrespective of mismatch repair deficiency-mediated acquired resistance to temozolomide. Mol Cancer Ther 2018,17(12),2551-2563","journal-title":"Mol Cancer Ther"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"4859","DOI":"10.1158\/1078-0432.CCR-07-4807","volume":"14","author":"Maxwell J.A.","year":"2008","unstructured":"Maxwell J.A.; Johnson S.P.; McLendon R.E.; Lister D.W.; Horne K.S.; Rasheed A.; Quinn J.A.; Ali-Osman F.; Friedman A.H.; Modrich P.L.; Bigner D.D.; Friedman H.S.; Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res 2008,14(15),4859-4868","journal-title":"Clin Cancer Res"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nrc3185","volume":"12","author":"Fu D.","year":"2012","unstructured":"Fu D.; Calvo J.A.; Samson L.D.; Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer 2012,12(2),104-120","journal-title":"Nat Rev Cancer"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1126\/science.1056154","volume":"291","author":"Wood R.D.","year":"2001","unstructured":"Wood R.D.; Mitchell M.; Sgouros J.; Lindahl T.; Human DNA repair genes. Science 2001,291(5507),1284-1289","journal-title":"Science"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.dnarep.2013.04.015","volume":"12","author":"Iyama T.","year":"2013","unstructured":"Iyama T.; Wilson D.M.; III DNA repair mechanisms in dividing and non-dividing cells. DNA Repair (Amst) 2013,12(8),620-636","journal-title":"DNA Repair (Amst)"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0076-6879(05)09029-4","volume":"409","author":"Dantzer F.","year":"2006","unstructured":"Dantzer F.; Am&#xE9; J.C.; Schreiber V.; Nakamura J.; M&#xE9;nissier-de Murcia J.; de Murcia G.; Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair. Methods Enzymol 2006,409,493-510","journal-title":"Methods Enzymol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.2174\/092986707780597998","volume":"14","author":"Aguilar-Quesada R.","year":"2007","unstructured":"Aguilar-Quesada R.; Mu&#xF1;oz-G&#xE1;mez J.A.; Mart&#xED;n-Oliva D.; Peralta-Leal A.; Quiles-P&#xE9;rez R.; Rodr&#xED;guez-Vargas J.M.; Ruiz de Almod&#xF3;var M.; Conde C.; Ruiz-Extremera A.; Oliver F.J.; Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation. Curr Med Chem 2007,14(11),1179-1187","journal-title":"Curr Med Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1158\/1078-0432.CCR-1144-3","volume":"10","author":"Curtin N.J.","year":"2004","unstructured":"Curtin N.J.; Wang L.Z.; Yiakouvaki A.; Kyle S.; Arris C.A.; Canan-Koch S.; Webber S.E.; Durkacz B.W.; Calvert H.A.; Hostomsky Z.; Newell D.R.; Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 2004,10(3),881-889","journal-title":"Clin Cancer Res"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2174\/092986709787002718","volume":"16","author":"Tentori L.","year":"2009","unstructured":"Tentori L.; Graziani G.; Recent approaches to improve the antitumor efficacy of temozolomide. Curr Med Chem 2009,16(2),245-257","journal-title":"Curr Med Chem"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-06-2260","volume":"13","author":"Ratnam K.","year":"2007","unstructured":"Ratnam K.; Low J.A.; Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007,13(5),1383-1388","journal-title":"Clin Cancer Res"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/jnci\/djh005","volume":"96","author":"Calabrese C.R.","year":"2004","unstructured":"Calabrese C.R.; Almassy R.; Barton S.; Batey M.A.; Calvert A.H.; Canan-Koch S.; Durkacz B.W.; Hostomsky Z.; Kumpf R.A.; Kyle S.; Li J.; Maegley K.; Newell D.R.; Notarianni E.; Stratford I.J.; Skalitzky D.; Thomas H.D.; Wang L.Z.; Webber S.E.; Williams K.J.; Curtin N.J.; Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004,96(1),56-67","journal-title":"J Natl Cancer Inst"},{"key":"ref=76","first-page":"371","volume":"2","author":"Miknyoczki S.J.","year":"2003","unstructured":"Miknyoczki S.J.; Jones-Bolin S.; Pritchard S.; Hunter K.; Zhao H.; Wan W.; Ator M.; Bihovsky R.; Hudkins R.; Chatterjee S.; Klein-Szanto A.; Dionne C.; Ruggeri B.; Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003,2(4),371-382","journal-title":"Mol Cancer Ther"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1158\/1535-7163.MCT-05-0128","volume":"4","author":"Cheng C.L.","year":"2005","unstructured":"Cheng C.L.; Johnson S.P.; Keir S.T.; Quinn J.A.; Ali-Osman F.; Szabo C.; Li H.; Salzman A.L.; Dolan M.E.; Modrich P.; Bigner D.D.; Friedman H.S.; Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 2005,4(9),1364-1368","journal-title":"Mol Cancer Ther"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.cell.2009.08.017","volume":"138","author":"Shackleton M.","year":"2009","unstructured":"Shackleton M.; Quintana E.; Fearon E.R.; Morrison S.J.; Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009,138(5),822-829","journal-title":"Cell"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/cr.2012.13","volume":"22","author":"Tang D.G.","year":"2012","unstructured":"Tang D.G.; Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012,22(3),457-472","journal-title":"Cell Res"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/35102167","volume":"414","author":"Reya T.","year":"2001","unstructured":"Reya T.; Morrison S.J.; Clarke M.F.; Weissman I.L.; Stem cells, cancer, and cancer stem cells. Nature 2001,414(6859),105-111","journal-title":"Nature"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.stem.2012.05.007","volume":"10","author":"Visvader J.E.","year":"2012","unstructured":"Visvader J.E.; Lindeman G.J.; Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012,10(6),717-728","journal-title":"Cell Stem Cell"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","volume":"14","author":"Kreso A.","year":"2014","unstructured":"Kreso A.; Dick J.E.; Evolution of the cancer stem cell model. Cell Stem Cell 2014,14(3),275-291","journal-title":"Cell Stem Cell"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature03128","volume":"432","author":"Singh S.K.","year":"2004","unstructured":"Singh S.K.; Hawkins C.; Clarke I.D.; Squire J.A.; Bayani J.; Hide T.; Henkelman R.M.; Cusimano M.D.; Dirks P.B.; Identification of human brain tumour initiating cells. Nature 2004,432(7015),396-401","journal-title":"Nature"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1634\/stemcells.2004-0232","volume":"23","author":"Kania G.","year":"2005","unstructured":"Kania G.; Corbeil D.; Fuchs J.; Tarasov K.V.; Blyszczuk P.; Huttner W.B.; Boheler K.R.; Wobus A.M.; Somatic stem cell marker prominin-1\/CD133 is expressed in embryonic stem cell-derived progenitors. Stem Cells 2005,23(6),791-804","journal-title":"Stem Cells"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-06-4180","volume":"67","author":"Beier D.","year":"2007","unstructured":"Beier D.; Hau P.; Proescholdt M.; Lohmeier A.; Wischhusen J.; Oefner P.J.; Aigner L.; Brawanski A.; Bogdahn U.; Beier C.P.; CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007,67(9),4010-4015","journal-title":"Cancer Res"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s13311-017-0524-0","volume":"14","author":"Abou-Antoun T.J.","year":"2017","unstructured":"Abou-Antoun T.J.; Hale J.S.; Lathia J.D.; Dombrowski S.M.; Brain Cancer Stem Cells in Adults and Children: Cell Biology and Therapeutic Implications. Neurotherapeutics 2017,14(2),372-384","journal-title":"Neurotherapeutics"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.stem.2015.02.015","volume":"16","author":"Plaks V.","year":"2015","unstructured":"Plaks V.; Kong N.; Werb Z.; The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 2015,16(3),225-238","journal-title":"Cell Stem Cell"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.3727\/096368914X684907","volume":"23","author":"Bryukhovetskiy A.","year":"2014","unstructured":"Bryukhovetskiy A.; Shevchenko V.; Kovalev S.; Chekhonin V.; Baklaushev V.; Bryukhovetskiy I.; Zhukova M.; To the novel paradigm of proteome-based cell therapy of tumors: through comparative proteome mapping of tumor stem cells and tissue-specific stem cells of humans. Cell Transplant 2014,23(Suppl. 1),S151-S170","journal-title":"Cell Transplant"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ccr.2008.12.006","volume":"15","author":"Alcantara Llaguno S.","year":"2009","unstructured":"Alcantara Llaguno S.; Chen J.; Kwon C.H.; Jackson E.L.; Li Y.; Burns D.K.; Alvarez-Buylla A.; Parada L.F.; Malignant astrocytomas originate from neural stem\/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 2009,15(1),45-56","journal-title":"Cancer Cell"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nature11287","volume":"488","author":"Chen J.","year":"2012","unstructured":"Chen J.; Li Y.; Yu T.S.; McKay R.M.; Burns D.K.; Kernie S.G.; Parada L.F.; A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012,488(7412),522-526","journal-title":"Nature"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1586\/14737175.2015.1051968","volume":"15","author":"Auffinger B.","year":"2015","unstructured":"Auffinger B.; Spencer D.; Pytel P.; Ahmed A.U.; Lesniak M.S.; The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Rev Neurother 2015,15(7),741-752","journal-title":"Expert Rev Neurother"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1093\/carcin\/bgu243","volume":"36","author":"Jackson M.","year":"2015","unstructured":"Jackson M.; Hassiotou F.; Nowak A.; Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target. Carcinogenesis 2015,36(2),177-185","journal-title":"Carcinogenesis"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","volume":"444","author":"Bao S.","year":"2006","unstructured":"Bao S.; Wu Q.; McLendon R.E.; Hao Y.; Shi Q.; Hjelmeland A.B.; Dewhirst M.W.; Bigner D.D.; Rich J.N.; Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006,444(7120),756-760","journal-title":"Nature"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.1158\/0008-5472.CAN-04-1364","volume":"64","author":"Galli R.","year":"2004","unstructured":"Galli R.; Binda E.; Orfanelli U.; Cipelletti B.; Gritti A.; De Vitis S.; Fiocco R.; Foroni C.; Dimeco F.; Vescovi A.; Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004,64(19),7011-7021","journal-title":"Cancer Res"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.bbrc.2015.06.137","volume":"468","author":"Kim S.S.","year":"2015","unstructured":"Kim S.S.; Harford J.B.; Pirollo K.F.; Chang E.H.; Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine. Biochem Biophys Res Commun 2015,468(3),485-489","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cas.12817","volume":"107","author":"Yoshida G.J.","year":"2016","unstructured":"Yoshida G.J.; Saya H.; Therapeutic strategies targeting cancer stem cells. Cancer Sci 2016,107(1),5-11","journal-title":"Cancer Sci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3892\/ijo.29.4.785","volume":"29","author":"Alvino E.","year":"2006","unstructured":"Alvino E.; Castiglia D.; Caporali S.; Pepponi R.; Caporaso P.; Lacal P.M.; Marra G.; Fischer F.; Zambruno G.; Bonmassar E.; Jiricny J.; D\u2019Atri S.; A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system. Int J Oncol 2006,29(4),785-797","journal-title":"Int J Oncol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10549-007-9690-9","volume":"110","author":"Bradshaw T.D.","year":"2008","unstructured":"Bradshaw T.D.; Stone E.L.; Trapani V.; Leong C-O.; Matthews C.S.; te Poele R.; Stevens M.F.G.; Mechanisms of acquired resistance to 2-(4-Amino-3-methylphenyl)benzothiazole in breast cancer cell lines. Breast Cancer Res Treat 2008,110(1),57-68","journal-title":"Breast Cancer Res Treat"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrc2818","volume":"10","author":"Huse J.T.","year":"2010","unstructured":"Huse J.T.; Holland E.C.; Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 2010,10(5),319-331","journal-title":"Nat Rev Cancer"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1158\/1541-7786.595.2.11","volume":"2","author":"Angers-Loustau A.","year":"2004","unstructured":"Angers-Loustau A.; Hering R.; Werbowetski T.E.; Kaplan D.R.; Del Maestro R.F.; SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. Mol Cancer Res 2004,2(11),595-605","journal-title":"Mol Cancer Res"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nbt.1513","volume":"27","author":"Du J.","year":"2009","unstructured":"Du J.; Bernasconi P.; Clauser K.R.; Mani D.R.; Finn S.P.; Beroukhim R.; Burns M.; Julian B.; Peng X.P.; Hieronymus H.; Maglathlin R.L.; Lewis T.A.; Liau L.M.; Nghiemphu P.; Mellinghoff I.K.; Louis D.N.; Loda M.; Carr S.A.; Kung A.L.; Golub T.R.; Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol 2009,27(1),77-83","journal-title":"Nat Biotechnol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"687","DOI":"10.4143\/crt.2014.320","volume":"48","author":"Eom K-Y.","year":"2016","unstructured":"Eom K-Y.; Cho B.J.; Choi E.J.; Kim J-H.; Chie E.K.; Wu H-G.; Kim I.H.; Paek S.H.; Kim J-S.; Kim I.A.; The Effect of chemoradiotherapy with SRC tyrosine kinase inhibitor, pp2 and temozolomide on malignant glioma cells in vitro and in vivo. Cancer Res Treat 2016,48(2),687-697","journal-title":"Cancer Res Treat"},{"key":"ref=103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056505","volume":"8","author":"Huveldt D.","year":"2013","unstructured":"Huveldt D.; Lewis-Tuffin L.J.; Carlson B.L.; Schroeder M.A.; Rodriguez F.; Giannini C.; Galanis E.; Sarkaria J.N.; Anastasiadis P.Z.; Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion. PLoS One 2013,8(2)","journal-title":"PLoS One"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.canlet.2010.04.013","volume":"296","author":"Ujifuku K.","year":"2010","unstructured":"Ujifuku K.; Mitsutake N.; Takakura S.; Matsuse M.; Saenko V.; Suzuki K.; Hayashi K.; Matsuo T.; Kamada K.; Nagata I.; Yamashita S.; miR-195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett 2010,296(2),241-248","journal-title":"Cancer Lett"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11060-018-2835-3","volume":"138","author":"Li Y.","year":"2018","unstructured":"Li Y.; Liu Y.; Ren J.; Deng S.; Yi G.; Guo M.; Shu S.; Zhao L.; Peng Y.; Qi S.; miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma. J Neurooncol 2018,138(3),499-508","journal-title":"J Neurooncol"},{"key":"ref=106","first-page":"4798","volume":"15","author":"Xu J.","year":"2018","unstructured":"Xu J.; Huang H.; Peng R.; Ding X.; Jiang B.; Yuan X.; Xi J.; MicroRNA-30a increases the chemosensitivity of U251 glioblastoma cells to temozolomide by directly targeting beclin 1 and inhibiting autophagy. Exp Ther Med 2018,15(6),4798-4804","journal-title":"Exp Ther Med"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4149\/neo_2010_03_264","volume":"57","author":"Slaby O.","year":"2010","unstructured":"Slaby O.; Lakomy R.; Fadrus P.; Hrstka R.; Kren L.; Lzicarova E.; Smrcka M.; Svoboda M.; Dolezalova H.; Novakova J.; Valik D.; Vyzula R.; Michalek J.; MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma 2010,57(3),264-269","journal-title":"Neoplasma"},{"key":"ref=108","first-page":"139a","volume":"18","author":"Yung A.","year":"1999","unstructured":"Yung A.; Levin V.A.; Albright R.; Olson J.; Fredericks R.; Fink K.; Prados M.; Brada M.; Spence A.; Brunner J.; Yue N.; Dugan M.; Zakneon. S. Randomized trial of Temodal (TEM) vs. Procarbazine (PCB) in glioblastoma multiforme (GBM) at first relapse. Proc Am Soc Clin Oncol 1999,18,139a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1200\/JCO.1999.17.9.2762","volume":"17","author":"Yung W.K.","year":"1999","unstructured":"Yung W.K.; Prados M.D.; Yaya-Tur R.; Rosenfeld S.S.; Brada M.; Friedman H.S.; Albright R.; Olson J.; Chang S.M.; O\u2019Neill A.M.; Friedman A.H.; Bruner J.; Yue N.; Dugan M.; Zaknoen S.; Levin V.A.; Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol Temodal Brain Tumor Group1999,17(9),2762-2771","journal-title":"J Clin Oncol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"Stupp R.","year":"2005","unstructured":"Stupp R.; Mason W.P.; van den Bent M.J.; Weller M.; Fisher B.; Taphoorn M.J.B.; Belanger K.; Brandes A.A.; Marosi C.; Bogdahn U.; Curschmann J.; Janzer R.C.; Ludwin S.K.; Gorlia T.; Allgeier A.; Lacombe D.; Cairncross J.G.; Eisenhauer E.; Mirimanoff R.O.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005,352(10),987-996","journal-title":"N Engl J Med"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"Louis D.N.","year":"2016","unstructured":"Louis D.N.; Perry A.; Reifenberger G.; von Deimling A.; Figarella-Branger D.; Cavenee W.K.; Ohgaki H.; Wiestler O.D.; Kleihues P.; Ellison D.W.; The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016,131(6),803-820","journal-title":"Acta Neuropathol"},{"key":"ref=112","author":"Mieskolainen M.","year":"2017","unstructured":"Mieskolainen M.; Molecular characteristics of malignant gliomas and their future perspectives - a review 2017","journal-title":"Molecular characteristics of malignant gliomas and their future perspectives - a review"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nrneurol.2015.171","volume":"11","author":"Westphal M.","year":"2015","unstructured":"Westphal M.; Lamszus K.; Circulating biomarkers for gliomas. Nat Rev Neurol 2015,11(10),556-566","journal-title":"Nat Rev Neurol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrneurol.2015.242","volume":"12","author":"Wen P.Y.","year":"2016","unstructured":"Wen P.Y.; Reardon D.A.; Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment. Nat Rev Neurol 2016,12(2),69-70","journal-title":"Nat Rev Neurol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3171\/2016.3.JNS152693","volume":"126","author":"Gainer J.L.","year":"2017","unstructured":"Gainer J.L.; Sheehan J.P.; Larner J.M.; Jones D.R.; Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme. J Neurosurg 2017,126(2),460-466","journal-title":"J Neurosurg"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1001\/jama.2015.16669","volume":"314","author":"Stupp R.","year":"2015","unstructured":"Stupp R.; Taillibert S.; Kanner A.A.; Kesari S.; Steinberg D.M.; Toms S.A.; Taylor L.P.; Lieberman F.; Silvani A.; Fink K.L.; Barnett G.H.; Zhu J.J.; Henson J.W.; Engelhard H.H.; Chen T.C.; Tran D.D.; Sroubek J.; Tran N.D.; Hottinger A.F.; Landolfi J.; Desai R.; Caroli M.; Kew Y.; Honnorat J.; Idbaih A.; Kirson E.D.; Weinberg U.; Palti Y.; Hegi M.E.; Ram Z.; Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: A Randomized Clinical Trial. JAMA 2015,314(23),2535-2543","journal-title":"JAMA"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"Gilbert M.R.","year":"2014","unstructured":"Gilbert M.R.; Dignam J.J.; Armstrong T.S.; Wefel J.S.; Blumenthal D.T.; Vogelbaum M.A.; Colman H.; Chakravarti A.; Pugh S.; Won M.; Jeraj R.; Brown P.D.; Jaeckle K.A.; Schiff D.; Stieber V.W.; Brachman D.G.; Werner-Wasik M.; Tremont-Lukats I.W.; Sulman E.P.; Aldape K.D.; Curran W.J.; Mehta M.P.; A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014,370(8),699-708","journal-title":"N Engl J Med"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"Chinot O.L.","year":"2014","unstructured":"Chinot O.L.; Wick W.; Mason W.; Henriksson R.; Saran F.; Nishikawa R.; Carpentier A.F.; Hoang-Xuan K.; Kavan P.; Cernea D.; Brandes A.A.; Hilton M.; Abrey L.; Cloughesy T.; Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014,370(8),709-722","journal-title":"N Engl J Med"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","volume":"13","author":"Donawho C.K.","year":"2007","unstructured":"Donawho C.K.; Luo Y.; Luo Y.; Penning T.D.; Bauch J.L.; Bouska J.J.; Bontcheva-Diaz V.D.; Cox B.F.; DeWeese T.L.; Dillehay L.E.; Ferguson D.C.; Ghoreishi-Haack N.S.; Grimm D.R.; Guan R.; Han E.K.; Holley-Shanks R.R.; Hristov B.; Idler K.B.; Jarvis K.; Johnson E.F.; Kleinberg L.R.; Klinghofer V.; Lasko L.M.; Liu X.; Marsh K.C.; McGonigal T.P.; Meulbroek J.A.; Olson A.M.; Palma J.P.; Rodriguez L.E.; Shi Y.; Stavropoulos J.A.; Tsurutani A.C.; Zhu G.D.; Rosenberg S.H.; Giranda V.L.; Frost D.J.; ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007,13(9),2728-2737","journal-title":"Clin Cancer Res"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/neuonc\/noaa016","volume":"22","author":"Baxter P.A.","year":"2020","unstructured":"Baxter P.A.; Su J.M.; Onar-Thomas A.; Billups C.A.; Li X.N.; Poussaint T.Y.; Smith E.R.; Thompson P.; Adesina A.; Ansell P.; Giranda V.; Paulino A.; Kilburn L.; Quaddoumi I.; Broniscer A.; Blaney S.M.; Dunkel I.J.; Fouladi M.; A phase I\/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study. Neuro-oncol 2020,22(6),875-885","journal-title":"Neuro-oncol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1200\/JCO.2017.35.15_suppl.2046","volume":"35","author":"Twelves C.","year":"2017","unstructured":"Twelves C.; Short S.; Wright S.; A two-part safety and exploratory efficacy randomized double-blind, placebo-controlled study of a 1:1 ratio of the cannabinoids cannabidiol and delta-9-tetrahydrocannabinol (CBD:THC) plus dose-intense temozolomide in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol 2017,35(15),2046-2046","journal-title":"J Clin Oncol"},{"key":"ref=122","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv369","volume":"108","author":"Gupta S.K.","year":"2015","unstructured":"Gupta S.K.; Kizilbash S.H.; Carlson B.L.; Mladek A.C.; Boakye-Agyeman F.; Bakken K.K.; Pokorny J.L.; Schroeder M.A.; Decker P.A.; Cen L.; Eckel-Passow J.E.; Sarkar G.; Ballman K.V.; Reid J.M.; Jenkins R.B.; Verhaak R.G.; Sulman E.P.; Kitange G.J.; Sarkaria J.N.; Delineation of MGMT hypermethylation as a biomarker for veliparib-mediated temozolomide-sensitizing therapy of glioblastoma. J Natl Cancer Inst 2015,108(5)","journal-title":"J Natl Cancer Inst"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1089\/cbr.2012.1276","volume":"27","author":"Claringbold P.G.","year":"2012","unstructured":"Claringbold P.G.; Price R.A.; Turner J.H.; Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Cancer Biother Radiopharm 2012,27(9),561-569","journal-title":"Cancer Biother Radiopharm"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1159\/000434723","volume":"103","author":"Claringbold P.G.","year":"2016","unstructured":"Claringbold P.G.; Turner J.H.; Pancreatic neuroendocrine tumor Control: durable objective response to combination 177lu-octreotate-capecitabine-temozolomide radiopeptide chemotherapy. Neuroendocrinology 2016,103(5),432-439","journal-title":"Neuroendocrinology"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ctrv.2012.06.002","volume":"39","author":"Tatar Z.","year":"2013","unstructured":"Tatar Z.; Thivat E.; Planchat E.; Gimbergues P.; Gadea E.; Abrial C.; Durando X.; Temozolomide and unusual indications: review of literature. Cancer Treat Rev 2013,39(2),125-135","journal-title":"Cancer Treat Rev"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fonc.2014.00248","volume":"4","author":"Owen S.","year":"2014","unstructured":"Owen S.; Souhami L.; The management of brain metastases in non-small cell lung cancer. Front Oncol 2014,4,248","journal-title":"Front Oncol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.3747\/co.24.3420","volume":"24","author":"Greenspoon J.N.","year":"2017","unstructured":"Greenspoon J.N.; Ellis P.M.; Pond G.; Caetano S.; Broomfield J.; Swaminath A.; Comparative survival in patients with brain metastases from non-small-cell lung cancer treated before and after implementation of radiosurgery. Curr Oncol 2017,24(2),e146-e151","journal-title":"Curr Oncol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.ijrobp.2012.11.042","volume":"85","author":"Sperduto P.W.","year":"2013","unstructured":"Sperduto P.W.; Wang M.; Robins H.I.; Schell M.C.; Werner-Wasik M.; Komaki R.; Souhami L.; Buyyounouski M.K.; Khuntia D.; Demas W.; Shah S.A.; Nedzi L.A.; Perry G.; Suh J.H.; Mehta M.P.; A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 2013,85(5),1312-1318","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cllc.2014.06.008","volume":"15","author":"Boggs D.H.","year":"2014","unstructured":"Boggs D.H.; Robins H.I.; Langer C.J.; Traynor A.M.; Berkowitz M.J.; Mehta M.P.; Strategies to prevent brain metastasis in high-risk non-small-cell lung cancer: lessons learned from a randomized study of maintenance temozolomide versus observation. Clin Lung Cancer 2014,15(6),433-440","journal-title":"Clin Lung Cancer"},{"key":"ref=130","first-page":"4711","volume":"37","author":"He Q.","year":"2017","unstructured":"He Q.; Bi X.; Ren C.; Wang Y.; Zou P.; Zhang H.; Chi N.; Xiu C.; Wang Y.; Tao R.; Phase II study of the efficacy and safety of high-dose pemetrexed in combination with cisplatin versus temozolomide for the treatment of non-small cell lung cancer with brain metastases. Anticancer Res 2017,37(8),4711-4716","journal-title":"Anticancer Res"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12885-018-4479-2","volume":"18","author":"Guida M.","year":"2018","unstructured":"Guida M.; Tommasi S.; Strippoli S.; Natalicchio M.I.; De Summa S.; Pinto R.; Cramarossa A.; Albano A.; Pisconti S.; Aieta M.; Ridolfi R.; Azzariti A.; Guida G.; Lorusso V.; Colucci G.; The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale). BMC Cancer 2018,18(1),552","journal-title":"BMC Cancer"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1093\/annonc\/mdv308","volume":"26","author":"Middleton M.R.","year":"2015","unstructured":"Middleton M.R.; Friedlander P.; Hamid O.; Daud A.; Plummer R.; Falotico N.; Chyla B.; Jiang F.; McKeegan E.; Mostafa N.M.; Zhu M.; Qian J.; McKee M.; Luo Y.; Giranda V.L.; McArthur G.A.; Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. Ann Oncol 2015,26(10),2173-2179","journal-title":"Ann Oncol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00280-015-2852-2","volume":"76","author":"Gabrielson A.","year":"2015","unstructured":"Gabrielson A.; Tesfaye A.A.; Marshall J.L.; Pishvaian M.J.; Smaglo B.; Jha R.; Dorsch-Vogel K.; Wang H.; He A.R.; Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2015,76(5),1073-1079","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1002\/cncr.31309","volume":"124","author":"Pishvaian M.J.","year":"2018","unstructured":"Pishvaian M.J.; Slack R.S.; Jiang W.; He A.R.; Hwang J.J.; Hankin A.; Dorsch-Vogel K.; Kukadiya D.; Weiner L.M.; Marshall J.L.; Brody J.R.; A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer. Cancer 2018,124(11),2337-2346","journal-title":"Cancer"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/annonc\/mdx505","volume":"29","author":"Han H.S.","year":"2018","unstructured":"Han H.S.; Di&#xE9;ras V.; Robson M.; Pal&#xE1;cov&#xE1; M.; Marcom P.K.; Jager A.; Bondarenko I.; Citrin D.; Campone M.; Telli M.L.; Domchek S.M.; Friedlander M.; Kaufman B.; Garber J.E.; Shparyk Y.; Chmielowska E.; Jakobsen E.H.; Kaklamani V.; Gradishar W.; Ratajczak C.K.; Nickner C.; Qin Q.; Qian J.; Shepherd S.P.; Isakoff S.J.; Puhalla S.; Veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in patients with BRCA1\/2 locally recurrent\/metastatic breast cancer: randomized phase II study. Ann Oncol 2018,29(1),154-161","journal-title":"Ann Oncol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s10637-014-0099-0","volume":"32","author":"Hussain M.","year":"2014","unstructured":"Hussain M.; Carducci M.A.; Slovin S.; Cetnar J.; Qian J.; McKeegan E.M.; Refici-Buhr M.; Chyla B.; Shepherd S.P.; Giranda V.L.; Alumkal J.J.; Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer. Invest New Drugs 2014,32(5),904-912","journal-title":"Invest New Drugs"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","volume":"36","author":"Pietanza M.C.","year":"2018","unstructured":"Pietanza M.C.; Waqar S.N.; Krug L.M.; Dowlati A.; Hann C.L.; Chiappori A.; Owonikoko T.K.; Woo K.M.; Cardnell R.J.; Fujimoto J.; Long L.; Diao L.; Wang J.; Bensman Y.; Hurtado B.; de Groot P.; Sulman E.P.; Wistuba I.I.; Chen A.; Fleisher M.; Heymach J.V.; Kris M.G.; Rudin C.M.; Byers L.A.; Randomized, double-blind, phase ii study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol 2018,36(23),2386-2394","journal-title":"J Clin Oncol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-11-2059","volume":"18","author":"Pietanza M.C.","year":"2012","unstructured":"Pietanza M.C.; Kadota K.; Huberman K.; Sima C.S.; Fiore J.J.; Sumner D.K.; Travis W.D.; Heguy A.; Ginsberg M.S.; Holodny A.I.; Chan T.A.; Rizvi N.A.; Azzoli C.G.; Riely G.J.; Kris M.G.; Krug L.M.; Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res 2012,18(4),1138-1145","journal-title":"Clin Cancer Res"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1158\/1535-7163.MCT-12-0710","volume":"12","author":"Hochhauser D.","year":"2013","unstructured":"Hochhauser D.; Glynne-Jones R.; Potter V.; Gr&#xE1;valos C.; Doyle T.J.; Pathiraja K.; Zhang Q.; Zhang L.; Sausville E.A.; A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther 2013,12(5),809-818","journal-title":"Mol Cancer Ther"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1038\/s41388-020-1208-5","volume":"39","author":"Struve N.","year":"2020","unstructured":"Struve N.; Binder Z.A.; Stead L.F.; Brend T.; Bagley S.J.; Faulkner C.; Ott L.; M&#xFC;ller-Goebel J.; Weik A.S.; Hoffer K.; Krug L.; Rieckmann T.; Bu&#xDF;mann L.; Henze M.; Morrissette J.J.D.; Kurian K.M.; Sch&#xFC;ller U.; Petersen C.; Rothkamm K.; O Rourke; D.M.; Short, S.C.; Kriegs, M. EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma. Oncogene 2020,39(15),3041-3055","journal-title":"Oncogene"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1158\/0008-5472.CAN-14-3616","volume":"75","author":"McFaline-Figueroa J.L.","year":"2015","unstructured":"McFaline-Figueroa J.L.; Braun C.J.; Stanciu M.; Nagel Z.D.; Mazzucato P.; Sangaraju D.; Cerniauskas E.; Barford K.; Vargas A.; Chen Y.; Tretyakova N.; Lees J.A.; Hemann M.T.; White F.M.; Samson L.D.; Minor changes in expression of the mismatch repair protein MSH2 exert a major impact on glioblastoma response to temozolomide. Cancer Res 2015,75(15),3127-3138","journal-title":"Cancer Res"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fonc.2012.00186","volume":"2","author":"Yoshimoto K.","year":"2012","unstructured":"Yoshimoto K.; Mizoguchi M.; Hata N.; Murata H.; Hatae R.; Amano T.; Nakamizo A.; Sasaki T.; Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma. Front Oncol 2012,2,186","journal-title":"Front Oncol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ijrobp.2016.05.009","volume":"96","author":"Jeong J.H.","year":"2016","unstructured":"Jeong J.H.; Hong Y.S.; Park Y.; Kim J.; Kim J.E.; Kim K.P.; Kim S.Y.; Park J.H.; Kim J.H.; Park I.J.; Lim S.B.; Yu C.S.; Kim J.C.; Kim T.W.; Phase 1 Study of preoperative chemoradiation therapy with temozolomide and capecitabine in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2016,96(2),289-295","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/bjc.2017.109","volume":"116","author":"Calegari M.A.","year":"2017","unstructured":"Calegari M.A.; Inno A.; Monterisi S.; Orlandi A.; Santini D.; Basso M.; Cassano A.; Martini M.; Cenci T.; de Pascalis I.; Camarda F.; Barbaro B.; Larocca L.M.; Gori S.; Tonini G.; Barone C.; A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. Br J Cancer 2017,116(10),1279-1286","journal-title":"Br J Cancer"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/annonc\/mdw071","volume":"27","author":"Amatu A.","year":"2016","unstructured":"Amatu A.; Barault L.; Moutinho C.; Cassingena A.; Bencardino K.; Ghezzi S.; Palmeri L.; Bonazzina E.; Tosi F.; Ricotta R.; Cipani T.; Crivori P.; Gatto R.; Chirico G.; Marrapese G.; Truini M.; Bardelli A.; Esteller M.; Di Nicolantonio F.; Sartore-Bianchi A.; Siena S.; Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. Ann Oncol 2016,27(6),1062-1067","journal-title":"Ann Oncol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/annonc\/mdt547","volume":"25","author":"Pietrantonio F.","year":"2014","unstructured":"Pietrantonio F.; Perrone F.; de Braud F.; Castano A.; Maggi C.; Bossi I.; Gevorgyan A.; Biondani P.; Pacifici M.; Busico A.; Gariboldi M.; Festinese F.; Tamborini E.; Di Bartolomeo M.; Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. Ann Oncol 2014,25(2),404-408","journal-title":"Ann Oncol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11523-015-0397-2","volume":"11","author":"Pietrantonio F.","year":"2016","unstructured":"Pietrantonio F.; de Braud F.; Milione M.; Maggi C.; Iacovelli R.; Dotti K.F.; Perrone F.; Tamborini E.; Caporale M.; Berenato R.; Leone G.; Pellegrinelli A.; Bossi I.; Festinese F.; Federici S.; Di Bartolomeo M.; Dose-dense temozolomide in patients with mgmt-silenced chemorefractory colorectal cancer. Target Oncol 2016,11(3),337-343","journal-title":"Target Oncol"},{"key":"ref=148","first-page":"1888","volume":"9","author":"Tentori L.","year":"1995","unstructured":"Tentori L.; Graziani G.; Gilberti S.; Lacal P.M.; Bonmassar E.; D\u2019Atri S.; Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia 1995,9(11),1888-1895","journal-title":"Leukemia"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/sj.leu.2404545","volume":"21","author":"Brandwein J.M.","year":"2007","unstructured":"Brandwein J.M.; Yang L.; Schimmer A.D.; Schuh A.C.; Gupta V.; Wells R.A.; Alibhai S.M.; Xu W.; Minden M.D.; A phase II study of temozolomide therapy for poor-risk patients aged >or=60 years with acute myeloid leukemia: low levels of MGMT predict for response. Leukemia 2007,21(4),821-824","journal-title":"Leukemia"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s00277-004-0925-0","volume":"83","author":"Lenz G.","year":"2004","unstructured":"Lenz G.; Hutter G.; Hiddemann W.; Dreyling M.; Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemia. Ann Hematol 2004,83(10),628-633","journal-title":"Ann Hematol"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/bjh.13094","volume":"167","author":"Brandwein J.M.","year":"2014","unstructured":"Brandwein J.M.; Kassis J.; Leber B.; Hogge D.; Howson-Jan K.; Minden M.D.; Galarneau A.; Pouliot J.F.; Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression. Br J Haematol 2014,167(5),664-670","journal-title":"Br J Haematol"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1158\/1078-0432.CCR-16-0984","volume":"23","author":"Gojo I.","year":"2017","unstructured":"Gojo I.; Beumer J.H.; Pratz K.W.; McDevitt M.A.; Baer M.R.; Blackford A.L.; Smith B.D.; Gore S.D.; Carraway H.E.; Showel M.M.; Levis M.J.; Dezern A.E.; Gladstone D.E.; Ji J.J.; Wang L.; Kinders R.J.; Pouquet M.; Ali-Walbi I.; Rudek M.A.; Poh W.; Herman J.G.; Karnitz L.M.; Kaufmann S.H.; Chen A.; Karp J.E.; A Phase 1 Study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clin Cancer Res 2017,23(3),697-706","journal-title":"Clin Cancer Res"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/ajh.22191","volume":"87","author":"Medeiros B.C.","year":"2012","unstructured":"Medeiros B.C.; Kohrt H.E.; Gotlib J.; Coutre S.E.; Zhang B.; Arber D.A.; Zehnder J.L.; Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. Am J Hematol 2012,87(1),45-50","journal-title":"Am J Hematol"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/sj.bjc.6605796","volume":"103","author":"Hassel J.C.","year":"2010","unstructured":"Hassel J.C.; Sucker A.; Edler L.; Kurzen H.; Moll I.; Stresemann C.; Spieth K.; Mauch C.; Rass K.; Dummer R.; Schadendorf D.; MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer 2010,103(6),820-826","journal-title":"Br J Cancer"},{"key":"ref=155","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017156","volume":"6","author":"Kreth S.","year":"2011","unstructured":"Kreth S.; Thon N.; Eigenbrod S.; Lutz J.; Ledderose C.; Egensperger R.; Tonn J.C.; Kretzschmar H.A.; Hinske L.C.; Kreth F.W.; O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS One 2011,6(2)","journal-title":"PLoS One"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1200\/JCO.2007.10.8217","volume":"25","author":"Ranson M.","year":"2007","unstructured":"Ranson M.; Hersey P.; Thompson D.; Beith J.; McArthur G.A.; Haydon A.; Davis I.D.; Kefford R.F.; Mortimer P.; Harris P.A.; Baka S.; Seebaran A.; Sabharwal A.; Watson A.J.; Margison G.P.; Middleton M.R.; Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 2007,25(18),2540-2545","journal-title":"J Clin Oncol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.18632\/oncotarget.1974","volume":"5","author":"Kushwaha D.","year":"2014","unstructured":"Kushwaha D.; Ramakrishnan V.; Ng K.; Steed T.; Nguyen T.; Futalan D.; Akers J.C.; Sarkaria J.; Jiang T.; Chowdhury D.; Carter B.S.; Chen C.C.; A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas. Oncotarget 2014,5(12),4026-4039","journal-title":"Oncotarget"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1038\/s41467-018-05373-4","volume":"9","author":"Chen X.","year":"2018","unstructured":"Chen X.; Zhang M.; Gan H.; Wang H.; Lee J.H.; Fang D.; Kitange G.J.; He L.; Hu Z.; Parney I.F.; Meyer F.B.; Giannini C.; Sarkaria J.N.; Zhang Z.; A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun 2018,9(1),2949","journal-title":"Nat Commun"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.dnarep.2008.09.003","volume":"8","author":"Roos W.P.","year":"2009","unstructured":"Roos W.P.; Nikolova T.; Quiros S.; Naumann S.C.; Kiedron O.; Zdzienicka M.Z.; Kaina B.; Brca2\/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair (Amst) 2009,8(1),72-86","journal-title":"DNA Repair (Amst)"},{"key":"ref=160","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024294","volume":"6","author":"Reuland S.N.","year":"2011","unstructured":"Reuland S.N.; Goldstein N.B.; Partyka K.A.; Cooper D.A.; Fujita M.; Norris D.A.; Shellman Y.G.; The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53. PLoS One 2011,6(8)","journal-title":"PLoS One"},{"key":"ref=161","first-page":"680","volume":"25","author":"Li R.H.","year":"2015","unstructured":"Li R.H.; Hou X.Y.; Yang C.S.; Liu W.L.; Tang J.Q.; Liu Y.Q.; Jiang G.; Temozolomide for treating malignant melanoma. J Coll Physicians Surg Pak 2015,25(9),680-688","journal-title":"J Coll Physicians Surg Pak"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1146\/annurev-pharmtox-010715-103456","volume":"56","author":"Tong R.","year":"2016","unstructured":"Tong R.; Kohane D.S.; New strategies in cancer nanomedicine. Annu Rev Pharmacol Toxicol 2016,56,41-57","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"Shi J.","year":"2017","unstructured":"Shi J.; Kantoff P.W.; Wooster R.; Farokhzad O.C.; Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 2017,17(1),20-37","journal-title":"Nat Rev Cancer"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"6674","DOI":"10.1021\/am5092165","volume":"7","author":"Fang C.","year":"2015","unstructured":"Fang C.; Wang K.; Stephen Z.R.; Mu Q.; Kievit F.M.; Chiu D.T.; Press O.W.; Zhang M.; Temozolomide nanoparticles for targeted glioblastoma therapy. ACS Appl Mater Interfaces 2015,7(12),6674-6682","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.4155\/fmc-2018-0521","volume":"11","author":"Ortiz R.","year":"2019","unstructured":"Ortiz R.; Cabeza L.; Perazzoli G.; Jimenez-Lopez J.; Garc&#xED;a-Pinel B.; Melguizo C.; Prados J.; Nanoformulations for glioblastoma multiforme: a new hope for treatment. Future Med Chem 2019,11(18),2459-2480","journal-title":"Future Med Chem"},{"key":"ref=166","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032568","volume":"7","author":"Wagner S.","year":"2012","unstructured":"Wagner S.; Zensi A.; Wien S.L.; Tschickardt S.E.; Maier W.; Vogel T.; Worek F.; Pietrzik C.U.; Kreuter J.; von Briesen H.; Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model. PLoS One 2012,7(3)","journal-title":"PLoS One"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12951-015-0114-4","volume":"13","author":"Dur&#xE1;n N.","year":"2015","unstructured":"Dur&#xE1;n N.; Silveira C.P.; Dur&#xE1;n M.; Martinez D.S.T.; Silver nanoparticle protein corona and toxicity: a mini-review. J Nanobiotechnology 2015,13,55","journal-title":"J Nanobiotechnology"},{"key":"ref=168","first-page":"445","volume":"6","author":"Tian X-H.","year":"2011","unstructured":"Tian X-H.; Lin X-N.; Wei F.; Feng W.; Huang Z.C.; Wang P.; Ren L.; Diao Y.; Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int J Nanomedicine 2011,6,445-452","journal-title":"Int J Nanomedicine"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1021\/acschemneuro.8b00339","volume":"9","author":"Arcella A.","year":"2018","unstructured":"Arcella A.; Palchetti S.; Digiacomo L.; Pozzi D.; Capriotti A.L.; Frati L.; Oliva M.A.; Tsaouli G.; Rota R.; Screpanti I.; Mahmoudi M.; Caracciolo G.; Brain targeting by liposome-biomolecular corona boosts anticancer efficacy of temozolomide in glioblastoma cells. ACS Chem Neurosci 2018,9(12),3166-3174","journal-title":"ACS Chem Neurosci"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3109\/10611861003587235","volume":"18","author":"Qin Y.","year":"2010","unstructured":"Qin Y.; Fan W.; Chen H.; Yao N.; Tang W.; Tang J.; Yuan W.; Kuai R.; Zhang Z.; Wu Y.; He Q.; In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes. J Drug Target 2010,18(7),536-549","journal-title":"J Drug Target"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1007\/s11095-010-0091-0","volume":"27","author":"Patil R.","year":"2010","unstructured":"Patil R.; Portilla-Arias J.; Ding H.; Inoue S.; Konda B.; Hu J.; Wawrowsky K.A.; Shin P.K.; Black K.L.; Holler E.; Ljubimova J.Y.; Temozolomide delivery to tumor cells by a multifunctional nano vehicle based on poly(&#x3B2;-L-malic acid). Pharm Res 2010,27(11),2317-2329","journal-title":"Pharm Res"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.2147\/IJN.S161163","volume":"13","author":"Zhang J.","year":"2018","unstructured":"Zhang J.; Xiao X.; Zhu J.; Gao Z.; Lai X.; Zhu X.; Mao G.; Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy. Int J Nanomedicine 2018,13,3039-3051","journal-title":"Int J Nanomedicine"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1038\/s41467-018-04315-4","volume":"9","author":"Lam F.C.","year":"2018","unstructured":"Lam F.C.; Morton S.W.; Wyckoff J.; Vu Han T-L.; Hwang M.K.; Maffa A.; Balkanska-Sinclair E.; Yaffe M.B.; Floyd S.R.; Hammond P.T.; Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat Commun 2018,9(1),1991","journal-title":"Nat Commun"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.canlet.2015.08.022","volume":"369","author":"Kim S.S.","year":"2015","unstructured":"Kim S.S.; Rait A.; Kim E.; DeMarco J.; Pirollo K.F.; Chang E.H.; Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. Cancer Lett 2015,369(1),250-258","journal-title":"Cancer Lett"},{"key":"ref=175","first-page":"1","volume":"15","author":"Jain A.","year":"2013","unstructured":"Jain A.; Singhai P.; Gurnany E.; Updhayay S.; Mody N.; Transferrin-tailored solid lipid nanoparticles as vectors for site-specific delivery of temozolomide to brain. J Nanopart Res 2013,15(1518),1-9","journal-title":"J Nanopart Res"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/glia.10083","volume":"39","author":"Lyons S.A.","year":"2002","unstructured":"Lyons S.A.; O\u2019Neal J.; Sontheimer H.; Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia 2002,39(2),162-173","journal-title":"Glia"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.bbrc.2018.12.158","volume":"509","author":"Zhang P.","year":"2019","unstructured":"Zhang P.; Tang M.; Huang Q.; Zhao G.; Huang N.; Zhang X.; Tan Y.; Cheng Y.; Combination of 3-methyladenine therapy and Asn-Gly-Arg (NGR)-modified mesoporous silica nanoparticles loaded with temozolomide for glioma therapy in vitro. Biochem Biophys Res Commun 2019,509(2),549-556","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.3109\/10717544.2015.1064186","volume":"23","author":"Song S.","year":"2016","unstructured":"Song S.; Mao G.; Du J.; Zhu X.; Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. Drug Deliv 2016,23(4),1404-1408","journal-title":"Drug Deliv"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.msec.2019.04.007","volume":"101","author":"Minaei S.E.","year":"2019","unstructured":"Minaei S.E.; Khoei S.; Khoee S.; Vafashoar F.; Mahabadi V.P.; In vitro anti-cancer efficacy of multi-functionalized magnetite nanoparticles combining alternating magnetic hyperthermia in glioblastoma cancer cells. Mater Sci Eng C 2019,101,575-587","journal-title":"Mater Sci Eng C"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.biocel.2019.01.010","volume":"108","author":"Emamgholizadeh Minaei S.","year":"2019","unstructured":"Emamgholizadeh Minaei S.; Khoei S.; Khoee S.; Karimi M.R.; Tri-block copolymer nanoparticles modified with folic acid for temozolomide delivery in glioblastoma. Int J Biochem Cell Biol 2019,108,72-83","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/01616412.2015.1133025","volume":"38","author":"Ananta J.S.","year":"2016","unstructured":"Ananta J.S.; Paulmurugan R.; Massoud T.F.; Temozolomide-loaded PLGA nanoparticles to treat glioblastoma cells: a biophysical and cell culture evaluation. Neurol Res 2016,38(1),51-59","journal-title":"Neurol Res"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.1021\/acs.molpharmaceut.5b00694","volume":"12","author":"Ananta J.S.","year":"2015","unstructured":"Ananta J.S.; Paulmurugan R.; Massoud T.F.; Nanoparticle-delivered antisense microrna-21 enhances the effects of temozolomide on glioblastoma cells. Mol Pharm 2015,12(12),4509-4517","journal-title":"Mol Pharm"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"21478","DOI":"10.18632\/oncotarget.25135","volume":"9","author":"Malhotra M.","year":"2018","unstructured":"Malhotra M.; Sekar T.V.; Ananta J.S.; Devulapally R.; Afjei R.; Babikir H.A.; Paulmurugan R.; Massoud T.F.; Targeted nanoparticle delivery of therapeutic antisense microRNAs presensitizes glioblastoma cells to lower effective doses of temozolomide in vitro and in a mouse model. Oncotarget 2018,9(30),21478-21494","journal-title":"Oncotarget"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijpharm.2018.04.062","volume":"545","author":"Ramalho M.J.","year":"2018","unstructured":"Ramalho M.J.; Sevin E.; Gosselet F.; Lima J.; Coelho M.A.N.; Loureiro J.A.; Pereira M.C.; Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment. Int J Pharm 2018,545(1-2),84-92","journal-title":"Int J Pharm"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3109\/02652048.2010.522257","volume":"28","author":"Jain A.","year":"2011","unstructured":"Jain A.; Chasoo G.; Singh S.K.; Saxena A.K.; Jain S.K.; Transferrin-appended PEGylated nanoparticles for temozolomide delivery to brain: in vitro characterisation. J Microencapsul 2011,28(1),21-28","journal-title":"J Microencapsul"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1080\/10717544.2018.1494226","volume":"25","author":"Chu L.","year":"2018","unstructured":"Chu L.; Wang A.; Ni L.; Yan X.; Song Y.; Zhao M.; Sun K.; Mu H.; Liu S.; Wu Z.; Zhang C.; Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting. Drug Deliv 2018,25(1),1634-1641","journal-title":"Drug Deliv"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1211\/0022357022539","volume":"56","author":"Illum L.","year":"2004","unstructured":"Illum L.; Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004,56(1),3-17","journal-title":"J Pharm Pharmacol"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.ijbiomac.2018.05.079","volume":"116","author":"Khan A.","year":"2018","unstructured":"Khan A.; Aqil M.; Imam S.S.; Ahad A.; Sultana Y.; Ali A.; Khan K.; Temozolomide loaded nano lipid based chitosan hydrogel for nose to brain delivery: Characterization, nasal absorption, histopathology and cell line study. Int J Biol Macromol 2018,116,1260-1267","journal-title":"Int J Biol Macromol"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"13925","DOI":"10.1038\/s41598-017-14129-x","volume":"7","author":"Tomaszowski K.H.","year":"2017","unstructured":"Tomaszowski K.H.; Hellmann N.; Ponath V.; Takatsu H.; Shin H.W.; Kaina B.; Uptake of glucose-conjugated MGMT inhibitors in cancer cells: role of flippases and type IV P-type ATPases. Sci Rep 2017,7(1),13925","journal-title":"Sci Rep"},{"key":"ref=190","first-page":"1394","volume":"23","author":"Roy S.K.","year":"1995","unstructured":"Roy S.K.; Gupta E.; Dolan M.E.; Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. Drug Metab Dispos 1995,23(12),1394-1399","journal-title":"Drug Metab Dispos"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"10383","DOI":"10.1021\/nn503735w","volume":"8","author":"Stephen Z.R.","year":"2014","unstructured":"Stephen Z.R.; Kievit F.M.; Veiseh O.; Chiarelli P.A.; Fang C.; Wang K.; Hatzinger S.J.; Ellenbogen R.G.; Silber J.R.; Zhang M.; Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O6-benzylguanine to brain tumors. ACS Nano 2014,8(10),10383-10395","journal-title":"ACS Nano"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1179\/1743132813Y.0000000191","volume":"35","author":"Vlachostergios P.J.","year":"2013","unstructured":"Vlachostergios P.J.; Hatzidaki E.; Papandreou C.N.; MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NF&#x3BA;B and mutant p53. Neurol Res 2013,35(8),879-882","journal-title":"Neurol Res"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s11307-014-0734-3","volume":"16","author":"Yoo B.","year":"2014","unstructured":"Yoo B.; Ifediba M.A.; Ghosh S.; Medarova Z.; Moore A.; Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ. Mol Imaging Biol 2014,16(5),680-689","journal-title":"Mol Imaging Biol"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"E1480","DOI":"10.1073\/pnas.1219142110","volume":"110","author":"Shchors K.","year":"2013","unstructured":"Shchors K.; Persson A.I.; Rostker F.; Tihan T.; Lyubynska N.; Li N.; Swigart L.B.; Berger M.S.; Hanahan D.; Weiss W.A.; Evan G.I.; Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. Proc Natl Acad Sci USA 2013,110(16),E1480-E1489","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=195","first-page":"1398","volume":"7","author":"Srivenugopal K.S.","year":"2001","unstructured":"Srivenugopal K.S.; Shou J.; Mullapudi S.R.; Lang F.F.; Rao J.S.; Ali-Osman F.; Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. Clin Cancer Res 2001,7(5),1398-1409","journal-title":"Clin Cancer Res"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.1021\/nn5014484","volume":"8","author":"Kim S.S.","year":"2014","unstructured":"Kim S.S.; Rait A.; Kim E.; Pirollo K.F.; Nishida M.; Farkas N.; Dagata J.A.; Chang E.H.; A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ACS Nano 2014,8(6),5494-5514","journal-title":"ACS Nano"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.nano.2014.09.005","volume":"11","author":"Kim S.S.","year":"2015","unstructured":"Kim S.S.; Rait A.; Kim E.; Pirollo K.F.; Chang E.H.A.; A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. Nanomedicine (Lond) 2015,11(2),301-311","journal-title":"Nanomedicine (Lond)"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1590\/S0102-86502012000600005","volume":"27","author":"Dag\u0131stan Y.","year":"2012","unstructured":"Dag\u0131stan Y.; Karaca I.; Bozkurt E.R.; Ozar E.; Yagmurlu K.; Toklu A.; Bilir A.; Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model. Acta Cir Bras 2012,27(6),383-387","journal-title":"Acta Cir Bras"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"887","DOI":"10.2217\/nnm-2017-0395","volume":"13","author":"Xie Y.","year":"2018","unstructured":"Xie Y.; Zeng X.; Wu X.; Hu J.; Zhu Y.; Yang X.; Hyperbaric oxygen as an adjuvant to temozolomide nanoparticle inhibits glioma growth by inducing G2\/M phase arrest. Nanomed (Lond) 2018,13(8),887-898","journal-title":"Nanomed (Lond)"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.2147\/IJN.S140462","volume":"13","author":"Graham K.","year":"2018","unstructured":"Graham K.; Unger E.; Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomedicine 2018,13,6049-6058","journal-title":"Int J Nanomedicine"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/10717544.2018.1534897","volume":"26","author":"Zong Z.","year":"2019","unstructured":"Zong Z.; Hua L.; Wang Z.; Xu H.; Ye C.; Pan B.; Zhao Z.; Zhang L.; Lu J.; Mei L.H.; Rutong Y.; Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy. Drug Deliv 2019,26(1),34-44","journal-title":"Drug Deliv"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrc1889","volume":"6","author":"Vescovi A.L.","year":"2006","unstructured":"Vescovi A.L.; Galli R.; Reynolds B.A.; Brain tumour stem cells. Nat Rev Cancer 2006,6(6),425-436","journal-title":"Nat Rev Cancer"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"74451","DOI":"10.18632\/oncotarget.20165","volume":"8","author":"Sun T.","year":"2017","unstructured":"Sun T.; Wu H.; Li Y.; Huang Y.; Yao L.; Chen X.; Han X.; Zhou Y.; Du Z.; Targeting transferrin receptor delivery of temozolomide for a potential glioma stem cell-mediated therapy. Oncotarget 2017,8(43),74451-74465","journal-title":"Oncotarget"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.1016\/j.bmcl.2016.08.064","volume":"26","author":"Rai R.","year":"2016","unstructured":"Rai R.; Banerjee M.; Wong D.H.; McCullagh E.; Gupta A.; Tripathi S.; Riquelme E.; Jangir R.; Yadav S.; Raja M.; Melkani P.; Dixit V.; Patil U.; Shrivastava R.; Middya S.; Olivares F.; Guerrero J.; Surya A.; Pham S.M.; Bernales S.; Protter A.A.; Hung D.T.; Chakravarty S.; Temozolomide analogs with improved brain\/plasma ratios - Exploring the possibility of enhancing the therapeutic index of temozolomide. Bioorg Med Chem Lett 2016,26(20),5103-5109","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000366131","volume":"88","author":"Zhang J.","year":"2015","unstructured":"Zhang J.; Hummersone M.; Matthews C.S.; Stevens M.F.; Bradshaw T.D.; N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death. Oncology 2015,88(1),28-48","journal-title":"Oncology"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1039\/C6MD00384B","volume":"7","author":"Cousin D.","year":"2016","unstructured":"Cousin D.; Zhang J.; Hummersone M.G.; Matthews C.S.; Frigerio M.; Bradshaw T.D.; Stevens. M.F.G. Antitumor imidazo[5,1-d]-1,2,3,5-tetrazines: compounds modified at the 3-position overcome resistance in human glioblastoma cell lines. MedChemComm 2016,7,2332-2343","journal-title":"MedChemComm"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3389\/fonc.2019.00485","volume":"9","author":"Yang Z.","year":"2019","unstructured":"Yang Z.; Wei D.; Dai X.; Stevens M.F.G.; Bradshaw T.D.; Luo Y.; Zhang J.; C8-Substituted imidazotetrazine analogs overcome temozolomide resistance by inducing DNA adducts and DNA damage. Front Oncol 2019,9,485","journal-title":"Front Oncol"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"12609","DOI":"10.1021\/acsami.0c01514","volume":"12","author":"Bouzinab K.","year":"2020","unstructured":"Bouzinab K.; Summers H.S.; Stevens M.F.G.; Moody C.J.; Thomas N.R.; Gershkovich P.; Weston N.; Ashford M.B.; Bradshaw T.D.; Turyanska L.; Delivery of temozolomide and N3-propargyl analog to brain tumors using an apoferritin nanocage. ACS Appl Mater Interfaces 2020,12(11),12609-12617","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12929-015-0175-6","volume":"22","author":"Chen T.C.","year":"2015","unstructured":"Chen T.C.; Cho H.Y.; Wang W.; Wetzel S.J.; Singh A.; Nguyen J.; Hofman F.M.; Sch&#xF6;nthal A.H.; Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo. J Biomed Sci 2015,22,71","journal-title":"J Biomed Sci"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/1471-2407-9-308","volume":"9","author":"Beier C.P.","year":"2009","unstructured":"Beier C.P.; Schmid C.; Gorlia T.; Kleinletzenberger C.; Beier D.; Grauer O.; Steinbrecher A.; Hirschmann B.; Brawanski A.; Dietmaier C.; Jauch-Worley T.; K&#xF6;lbl O.; Pietsch T.; Proescholdt M.; R&#xFC;mmele P.; Muigg A.; Stockhammer G.; Hegi M.; Bogdahn U.; Hau P.; RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study. BMC Cancer 2009,9(308),308","journal-title":"BMC Cancer"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/183194","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/183194\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/183194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T10:35:11Z","timestamp":1667126111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/183194\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":210,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x18666200626204005","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-05-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}